ArticlePloS one2017
Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Pooled it
- Influenza virus-like particles presentingNanomedicine (London, England) · 2025Article
- Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 ofVaccines · 2025Article
- Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.Parasites, hosts and diseases · 2023Article
- Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.Pharmaceutics · 2023Article
- Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein.PloS one · 2023Article
- Recombinant Vaccinia Virus ExpressingTropical medicine and infectious disease · 2022Article
- Influenza virus-like particle vaccine containing both apical membrane antigen 1 and microneme-associated antigen proteins of Plasmodium berghei confers protection in mice.BMC immunology · 2022Article
- Protection and Alleviated Inflammation Induced by Virus-like Particle Vaccines ContainingVaccines · 2022Article
- Detection of Toxoplasma gondii Infections using Virus-Like Particles Displaying T. gondii ROP4 Antigen.The Korean journal of parasitology · 2021Article
- Passive Immunity and Antibody Response Induced byVaccines · 2021Article
- Advances inVaccines · 2021Review
- Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.Current topics in microbiology and immunology · 2021Review
- Protective Immunity Induced by Virus-Like Particle Containing Merozoite Surface Protein 9 ofVaccines · 2020Article
- Protection induced by malaria virus-like particles containing codon-optimized AMA-1 of Plasmodium berghei.Malaria journal · 2019Article
- Virus-like Particle Vaccine Containing Toxoplasma gondii Rhoptry Protein 13 Induces Protection against T. gondii ME49 Infection in Mice.The Korean journal of parasitology · 2019Article
- Parasite Infiltration and Apoptosis in Spleen upon Toxoplasma gondii Infection.The Korean journal of parasitology · 2019Article
- Influenza Virus-Like Particles Presenting bothPharmaceutics · 2019Article
- Previous Infection with Plasmodium berghei Confers Resistance to Toxoplasma gondii Infection in Mice.The Korean journal of parasitology · 2019Article
- Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii (T. gondii) microneme protein 8 (MIC8) represents a novel, functional distinct invasion factor. In this study, we generated virus-like particles (VLPs) targeting Toxoplasma gondii MIC8 for the first time, and investigated the protection against highly virulent RH strain of T. gondii in a mouse model. We found that VLP vaccination induced Toxoplasma gondii-specific IgG and IgG1 antibody responses in the sera. Upon challenge infection with RH strain of T. gondii tachyzoites, vaccinated mice showed a significant increase of both IgG antibodies in sera and IgA antibodies in feces compared to those before challenge, and a rapid expansion of both germinal center B cell (B220+, GL7+) and T cell (CD4+, CD8+) populations. Importantly, intranasally immunized mice showed higher neutralizing antibodies and displayed no proinflammatory cytokine IFN-γ in the spleen. Mice were completely protected from a lethal challenge infection with the highly virulent T. gondii (RH) showing no body weight loss (100% survival). Our study shows the effective protection against T. gondii infection provided by VLPs containing microneme protein 8 of T. gondii, thus indicating a potential T. gondii vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.